Patents Examined by Tracy Vivlemore
  • Pesticidally active pyrazole derivatives
    Patent number: 11252963
    Abstract: Compounds of formula (I) as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control pests such as insect, acarine, mollusc and nematode pests.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: February 22, 2022
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Denis Gribkov, Myriem El Qacemi, André Stoller, André Jeanguenat, Aurelien Bigot
  • Compounds and methods for inhibiting JAK
    Patent number: 11247983
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: February 15, 2022
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Annika Birgitta Margareta Astrand, Neil Patrick Grimster, Sameer Kawatkar, Jason Grant Kettle, Magnus K. Nilsson, Linette Ruston, Qibin Su, Melissa Vasbinder, Jon James Winter-Holt, Richard Donald Woessner, Claudio Edmundo Chuaqui, James McCabe
  • Microrna let-7 and transforming growth factor beta receptor III axis as target for cardiac injuries
    Patent number: 11246883
    Abstract: Methods for ameliorating cardiac is juries such as myocardial infarction by either enhancing the activity of a let-7 microRNA or inhibiting the activity of transformation growth factor beta receptor III (T GFBR3). Also provided herein are assay methods for detecting the level of TGFBR3, the level of a let-7 microRNA, or both in a biological sample.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: February 15, 2022
    Assignee: Academia Sinica
    Inventors: Patrick C. H. Hsieh, Chen-Yun Chen, Yu-Che Cheng
  • Heterocyclic LSF inhibitors and their uses
    Patent number: 11242353
    Abstract: The present invention is directed to heterocyclic SV40 Factor (LSF) inhibitors and their uses. In some implementations, the present invention discloses small-molecule compounds of Formula (I). In some implementations, the compounds of Formula (I) are used in methods for inhibiting LSF in a subject. In some implementations, the compounds of Formula (I) are used in methods for treating cancer in a subject.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: February 8, 2022
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott E. Schaus, Ulla Hansen, John A. Kavouris, Emily A. York, Niranjana Pokharel
  • Benzimidazole compounds as agricultural chemicals
    Patent number: 11241013
    Abstract: The present invention relates to benzimidazole ethers and related compounds which are of use in the field of agriculture as fungicides.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: February 8, 2022
    Inventors: Christopher John Urch, Roger John Butlin, Stephania Christou, Rebecca Kathryn Booth
  • Heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and/or 2(HDAC1-2)
    Patent number: 11241428
    Abstract: The present invention relates to novel heteroaryl amide derivatives of formula (1) as selective inhibitors of histone deacetylase 1 and 2 (hdac1-2) to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said compounds for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by inhibition the activity of histone deacetylase class I, particularly HDAC1 and HDAC2, such as cancer, neurodegenerative diseases, Infectious diseases, inflammatory diseases, heart failure and cardiac hypertrophy, diabetes, polycystic kidney disease, sickle cell disease and ?-thalassemia disease and to methods for the treatment of the diseases mentioned above.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: February 8, 2022
    Assignee: Medibiofarma, S.L.
    Inventors: Julio Castro Palomino Laria, Juan Camacho Gómez, Rodolfo Rodríguez Iglesias
  • Therapeutic targeting of a microRNA to treat Duchenne muscular dystrophy
    Patent number: 11236336
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: February 1, 2022
    Assignees: The General Hospital Corporation, Aalborg University
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • Bifunctional compounds
    Patent number: 11236103
    Abstract: The present application provides compounds that modulate CDK protein function. Methods of making the compounds, compositions containing the compounds, and uses of the compounds for treating or ameliorating of diseases, disorders, or conditions associated with CDK proteins, are also disclosed.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: February 1, 2022
    Assignee: BioTheryX, Inc.
    Inventors: Kyle W. H. Chan, Aparajita Hoskote Chourasia, Paul E. Erdman, Leah Fung, David Aaron Hecht, Frank Mercurio, Robert Sullivan, Joseph P. Vacca
  • Magnetic composite particles, method for manufacturing the same, and immunoassay particles
    Patent number: 11231414
    Abstract: To provide magnetic composite particles which can be separated from a sample solution in a short period of time using magnetism, and furthermore, have an excellent dispersion stability in the sample solution, which are magnetic composite particles in which an outer shell is formed on surfaces of core particles containing an inorganic oxide or a polymer, wherein the outer shell comprises magnetic nanoparticles and a silicon compound, the value of the volume average particle diameter (dTEM) of the magnetic composite particles measured by a transmission electron microscope is 30 nm or more to 210 nm or less, and the value of (dDLS)/(dTEM) which is the ratio of the value of the particle diameter (dDLS) of the particles measured by a dynamic light scattering method and the value of the volume average particle diameter (dTEM) is 2.0 or less.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: January 25, 2022
    Assignees: TOHOKU UNIVERSITY, DOWA ELECTRONICS MATERIALS CO., LTD.
    Inventors: Daisuke Nagao, Mikio Konno, Haruyuki Ishii, Kumiko Hayashi, Natsuki Kohama, Takayuki Yoshida, Toshihiko Ueyama
  • Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
    Patent number: 11230554
    Abstract: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: January 25, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Hui Li, Somasekhar Bhamidipati, David Carroll, Catherine Sylvain, Jeffrey Clough, Holger Keim
  • Oligonucleotide compounds for targeting huntingtin mRNA
    Patent number: 11230713
    Abstract: This disclosure relates to novel huntingtin targets. Novel oligonucleotides for the treatment of Huntington's disease are also provided.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: January 25, 2022
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Anastasia Khvorova, Neil Aronin, Julia Alterman
  • Compounds and methods for reducing SNCA expression
    Patent number: 11230712
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SNCA mRNA in a cell or animal, and in certain instances reducing the amount of alpha-synuclein protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include motor dysfunction, aggregation of alpha-synuclein, neurodegeneration, cognitive decline and dementia. Such neurodegenerative diseases include Parkinson's disease, dementia with Lewy bodies, diffuse Lewy body disease, pure autonomic failure, multiple system atrophy, neuronopathic Gaucher's disease and Alzheimer's disease.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: January 25, 2022
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Holly Kordasiewicz, Tracy A. Cole
  • Substituted tetrahydroquinolinone compounds as ROR gamma modulators
    Patent number: 11229636
    Abstract: The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as ROR? modulators. These compounds are useful in the treatment and prevention of diseases and/or disorder, in particular their use in diseases and/or disorder mediated by ROR? receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted tetrahydroquinolinone or related compounds of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: January 25, 2022
    Assignee: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
    Inventors: Ravi Kotrabasaiah Ujjinamatada, Chetan Pandit
  • Pyrimidines and variants thereof, and uses therefor
    Patent number: 11230532
    Abstract: The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof, for example, for the potential treatment of diseases associated with P2X purinergic receptors: In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: January 25, 2022
    Assignee: AFFERENT PHARMACEUTICALS, INC.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • Compounds and methods for trans-membrane delivery of molecules
    Patent number: 11230710
    Abstract: A system for delivery of drugs, and especially genetic drugs such as siRNA or antisense oligonucleotides (ASO) across biological membranes is provided. It comprises a trans-membrane delivery moiety, energized by the membrane internal electrical field, and a redox-sensitive disulfide moiety, designed to be reduced at the cytoplasm, thus releasing the cargo drug to exert its pharmaceutical effects at its target sites.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: January 25, 2022
    Assignee: Aposense Ltd
    Inventors: Ilan Ziv, Joseph Dubrovsky, Hagit Grimberg
  • Concatemeric RNA molecules, compositions, and methods and uses thereof
    Patent number: 11230708
    Abstract: The present invention relates to concatemeric RNA molecules, compositions, particles, and methods of uses thereof.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: January 25, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Paula T. Hammond Cunningham, Connie Wu, Kevin E. Shopsowitz
  • Compact and homogeneous quantum dots and methods of making the same
    Patent number: 11226336
    Abstract: The present disclosure provides quantum dots and methods of making the quantum dots comprising a substantially homogeneous population of monomeric nanocrystals, of a very small size, about 7 nm to about 12 nm in diameter. The method comprises mixing a nanocrystal coated with weakly binding ligands or ions with a polymer in a solution and incubating at a temperature greater than about 100° C., thereby forming a quantum dot having a substantially homogenous population of monomeric nanocrystals. The quantum dots can be further conjugated to bioaffinity molecules, enabling broad utilization of compact, biofunctional quantum dots for studying crowded macromolecular environments.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: January 18, 2022
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Andrew M. Smith, Chunlai Tu, Liang Ma
  • Antibodies to olanzapine haptens and use thereof
    Patent number: 11226345
    Abstract: Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: January 18, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Matthew Garrett Donahue, Yong Gong
  • Metallic nanoparticle synthesis with carbohydrate capping agent
    Patent number: 11221330
    Abstract: The disclosure relates to metal nanoparticle compositions and their methods of formation and use, in particular gold nanoparticles (AuNP) and gold-coated magnetic nanoparticles. Compositions according to the disclosure include aqueous suspensions of metal nanoparticles that are stabilized with one or more carbohydrate capping agents and/or that are functionalized with one or more binding pair members for capture/detection of a target analyte. The nanoparticle suspensions are stable for extended periods and can be functionalized as desired at a later point in time, typically prior to use in an assay for the detection of a target biological analyte. The stable nanoparticle suspension can be formed by the aqueous reduction of oxidized metal precursors at non-acidic pH values in the presence of a carbohydrate-based capping agent such as dextrin or other oligosaccharides.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: January 11, 2022
    Assignee: BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
    Inventors: Evangelyn C. Alocilja, Michael J. Anderson, Edith Torres-Chavolla
  • Cyclin dependent kinase inhibitors
    Patent number: 11220494
    Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: January 11, 2022
    Assignee: Pfizer Inc.
    Inventors: Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer